PMID- 37670621
OWN - NLM
STAT- MEDLINE
DCOM- 20230907
LR  - 20230907
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 52
IP  - 9
DP  - 2023 Sep 8
TI  - [Nodal T-follicular helper cell lymphoma, angioimmunoblastic-type associated with 
      diffuse large B-cell lymphoma: a clinicopathological study].
PG  - 918-923
LID - 10.3760/cma.j.cn112151-20221206-01024 [doi]
AB  - Objective: To investigate the clinicopathological features and molecular genetics 
      of diffuse large B-cell lymphomas (DLBCL) with concurrent or secondary to nodal 
      T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI). Methods: 
      The clinicopathological features and molecular genetics of DLBCL associated with 
      nTFHL-AI diagnosed between January 2015 and October 2022 at the First Affiliated 
      Hospital of Zhengzhou University were analyzed using histology, 
      immunohistochemistry, PCR, EBV-encoded RNA in situ hybridization and fluorescence 
      in situ hybridization (FISH). Clinical information was collected and analyzed. 
      Results: A total of 6 cases including 3 nTFHL-AI with secondary DLBCL and 3 
      composite lymphomas were reviewed. There were 4 male and 2 female patients, whose 
      ages ranged from 40 to 74 years (median 57 years). All patients presented with 
      nodal lesions at an advanced Ann Arbor stage Ⅲ/Ⅳ (6/6). Bone marrow involvement 
      was detected in 4 patients. All cases showed typical histologic and 
      immunophenotypic characteristics of nTFHL-AI. Among them, 5 cases of DLBCL with 
      concurrent nTFHL-AI exhibited numerous large atypical lymphoid cells and the 
      tumor cells were CD20 and CD79alpha positive. The only case of DLBCL secondary to 
      nTFHL-AI showed plasma cell differentiation and reduced expression of CD20. All 
      of cases were activated B-cell (ABC)/non-germinal center B-cell (non-GCB) 
      subtype. Three of the 6 cases were EBV positive with>100 positive cells/high 
      power field, meeting the diagnostic criteria of EBV(+)DLBCL. The expression of 
      MYC and CD30 protein in the DLBCL region was higher than that in the nTFHL-AI 
      region (n=5). C-MYC, bcl-6 and bcl-2 translocations were not detected in the 4 
      cases that were subject to FISH. Four of the 6 patients received chemotherapy 
      after diagnosis. For the DLBCL cases of nTFHL-AI with secondary DLBCL, the 
      interval was between 2-20 months. During the follow-up period ranging from 3-29 
      months, 3 of the 6 patients died of the disease. Conclusions: DLBCL associated 
      with nTFHL-AI is very rare. The expansion of EBV-infected B cells in nTFHL-AI may 
      progress to secondary EBV(+)DLBCL. However, EBV-negative cases have also been 
      reported, suggesting possible other mechanisms. The up-regulation of MYC 
      expression in these cases suggests a possible role in B-cell lymphomagenesis. 
      Clinicians should be aware that another biopsy is still necessary to rule out 
      concurrent or secondary DLBCL when nodal and extranodal lesions are noted after 
      nTFHL-AI treatment.
FAU - Wang, G N
AU  - Wang GN
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhao, W G
AU  - Zhao WG
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, D D
AU  - Zhang DD
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, Y P
AU  - Zhang YP
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Liu, E J
AU  - Liu EJ
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Lu, S S
AU  - Lu SS
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Li, W C
AU  - Li WC
AD  - Department of Pathology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
SB  - IM
MH  - Female
MH  - Male
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse
MH  - B-Lymphocytes
MH  - Biopsy
MH  - T-Lymphocytes, Helper-Inducer
EDAT- 2023/09/06 06:42
MHDA- 2023/09/07 06:42
CRDT- 2023/09/06 03:21
PHST- 2023/09/07 06:42 [medline]
PHST- 2023/09/06 06:42 [pubmed]
PHST- 2023/09/06 03:21 [entrez]
AID - 10.3760/cma.j.cn112151-20221206-01024 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2023 Sep 8;52(9):918-923. doi: 
      10.3760/cma.j.cn112151-20221206-01024.